{"altmetric_id": 89296426, "counts": {"readers": {"citeulike": "0", "mendeley": "45", "connotea": "0"}, "total": {"posts_count": 211}, "twitter": {"unique_users_count": 130, "posts_count": 168}, "news": {"unique_users_count": 19, "unique_users": ["globenewswire", "marketscreener", "benzinga", "morning_star", "crwe_world", "one_news_page", "the_street", "biz_wire_express", "jotup", "trialsite_news", "the_medical_news", "yahoo_finance_usa", "biospace", "pharmalive", "biomed_reports", "einpresswire", "firstword_pharma", "lessentiel", "yahoo_news"], "posts_count": 42}, "blogs": {"unique_users_count": 1, "unique_users": [51890], "posts_count": 1}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Drayman, Nir", "Jones, Krysten A.", "Azizi, Saara-Anne", "Froggatt, Heather M.", "Tan, Kemin", "Maltseva, Natalia Ivanovna", "Chen, Siquan", "Nicolaescu, Vlad", "Dvorkin, Steve", "Furlong, Kevin", "Kathayat, Rahul S.", "Firpo, Mason R.", "Mastrodomenico, Vincent", "Bruce, Emily A.", "Schmidt, Madaline M.", "Jedrzejczak, Robert", "Mu\u00f1oz-Al\u00eda, Miguel \u00c1.", "Schuster, Brooke", "Nair, Vishnu", "Botten, Jason W.", "Brooke, Christopher B.", "Baker, Susan C.", "Mounce, Bryan C.", "Heaton, Nicholas S.", "Dickinson, Bryan C.", "Jaochimiak, Andrzej", "Randall, Glenn", "Tay, Sava\u015f"], "doi": "10.1101/2020.08.31.274639", "first_seen_on": "2020-09-01T22:19:25+00:00", "funders": ["niaid"], "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1618469504, "links": ["https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1", "https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1?rss=1%22", "https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1#disqus_thread", "https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1?rss=1&utm_source=dlvr.it&utm_medium=twitter", "http://dx.doi.org/10.1101/2020.08.31.274639", "https://doi.org/10.1101/2020.08.31.274639", "https://www.biorxiv.org/content/10.1101/2020.08.31.274639v1.full.pdf", "https://pubmed.ncbi.nlm.nih.gov/32908976/", "https://www.bioRxiv.org/content/10.1101/2020.08.31.274639v1", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480023/"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/09/01/2020.08.31.274639.full.pdf", "pmid": "32908976", "publisher": "Cold Spring Harbor Laboratory", "title": "Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/46f2c1f4-7907-32b2-95eb-cf61bbf0c87b/"}, "altmetric_score": {"score": 219.604, "score_history": {"1y": 219.604, "6m": 137.3, "3m": 101.6, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 219.604}, "context_for_score": {"all": {"total_number_of_other_articles": 17730520, "mean": 9.446781885247, "rank": 94732, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17636253, "rank_type": "exact", "sample_size": 17730520, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 307140, "mean": 18.1063295826, "rank": 3707, "this_scored_higher_than_pct": 98, "this_scored_higher_than": 303429, "rank_type": "exact", "sample_size": 307140, "percentile": 98}, "this_journal": {"total_number_of_other_articles": 121238, "mean": 13.888680743661, "rank": 543, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 120704, "rank_type": "exact", "sample_size": 121238, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 9092, "mean": 13.148261328641, "rank": 40, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 9052, "rank_type": "exact", "sample_size": 9092, "percentile": 99}}}, "demographics": {"poster_types": {"member_of_the_public": 86, "researcher": 41, "practitioner": 1, "science_communicator": 2}, "users": {"twitter": {"cohorts": {"Members of the public": 86, "Scientists": 41, "Science communicators (journalists, bloggers, editors)": 2, "Practitioners (doctors, other healthcare professionals)": 1}}, "mendeley": {"by_status": {"Student  > Postgraduate": 1, "Professor > Associate Professor": 2, "Researcher": 10, "Student  > Master": 4, "Student  > Ph. D. Student": 5, "Professor": 1, "Student  > Bachelor": 6, "Student  > Doctoral Student": 1, "Lecturer": 1, "Other": 2, "Librarian": 2}, "by_discipline": {"Chemistry": 6, "Medicine and Dentistry": 8, "Social Sciences": 1, "Immunology and Microbiology": 3, "Computer Science": 2, "Agricultural and Biological Sciences": 4, "Nursing and Health Professions": 1, "Biochemistry, Genetics and Molecular Biology": 4, "Pharmacology, Toxicology and Pharmaceutical Science": 3, "Environmental Science": 1}}}, "geo": {"twitter": {"US": 36, "IN": 2, "JP": 1, "CA": 1, "AU": 2, "IL": 4, "GB": 9, "FR": 9, "NL": 1, "DE": 2, "SG": 1, "CH": 2, "AD": 1, "IT": 2, "ES": 1, "KE": 1, "ET": 1, "EC": 1, "BE": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1300920373421236224"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "748908558066982916"}, "tweet_id": "1300920374591447042"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "373113388"}, "tweet_id": "1300920585334202369"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1239643988707160064"}, "tweet_id": "1300920805015126016"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3793892958"}, "tweet_id": "1300922214586355712"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1300927126623989760"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "747809624800268288"}, "tweet_id": "1300930553592664064"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2669568144"}, "tweet_id": "1300931573705920517"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "917056588392947712"}, "tweet_id": "1300933846020616192"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1300935698653032449"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "14762341"}, "tweet_id": "1300935911346237440"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1099714500025114624"}, "tweet_id": "1300936417984557057"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "750463426900688900"}, "tweet_id": "1300941693290795009"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "306929586"}, "tweet_id": "1300941755974590466"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "506407977"}, "tweet_id": "1300943010205700096"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1059441821569441792"}, "tweet_id": "1300946577230618629"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "819617443287093248"}, "tweet_id": "1300947138675978247"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1103075749072957440"}, "tweet_id": "1300950135090937857"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4777814309"}, "tweet_id": "1300950915848036358"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1300951616045166594"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1570478749"}, "tweet_id": "1300953713171992576"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "90941336"}, "tweet_id": "1300957990195920897"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4725717588"}, "tweet_id": "1300963725390864384"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "747809624800268288"}, "tweet_id": "1300968378891407360"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3058970334"}, "tweet_id": "1300974871497699329"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1240995101234434050"}, "tweet_id": "1300975737449533447"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "246033568"}, "tweet_id": "1300982229888245760"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2414645220"}, "tweet_id": "1300990139649454080"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1105157954271997952"}, "tweet_id": "1300992794958290946"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "987052986206633984"}, "tweet_id": "1300995908243341314"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1113537091466596353"}, "tweet_id": "1301005053453627392"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "599345003"}, "tweet_id": "1301010187721961472"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "910951302351515648"}, "tweet_id": "1301015728024424450"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1256280966101942273"}, "tweet_id": "1301016820904796161"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "955762753251282945"}, "tweet_id": "1301021491245453312"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1216139546"}, "tweet_id": "1301026729310457858"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "330404705"}, "tweet_id": "1301028357241556992"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "925109950959046656"}, "tweet_id": "1301029107501871105"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "984172899308392448"}, "tweet_id": "1301029236069806081"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "58569754"}, "tweet_id": "1301031897456349184"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2280525792"}, "tweet_id": "1301037388949487617"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3293760129"}, "tweet_id": "1301039606100525057"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "468073662"}, "tweet_id": "1301045341635121153"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1074457014"}, "tweet_id": "1301057897762299907"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "428021075"}, "tweet_id": "1301062387034976258"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1011960352916103168"}, "tweet_id": "1301074372841615360"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "471343985"}, "tweet_id": "1301076279354167297"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "402996114"}, "tweet_id": "1301076787963854849"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1003004687573020672"}, "tweet_id": "1301090514746437632"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3142088601"}, "tweet_id": "1301097926605918208"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "608568292"}, "tweet_id": "1301100962472497152"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2650200070"}, "tweet_id": "1301103171901718529"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "72137855"}, "tweet_id": "1301104820011626496"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "218369115"}, "tweet_id": "1301105682029051905"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1041884401859088384"}, "tweet_id": "1301105941241237504"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "981118005978501120"}, "tweet_id": "1301113163635621890"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "999100031239118853"}, "tweet_id": "1301120080600858624"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1301120375200403463"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1301120397983842306"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "718066634334846976"}, "tweet_id": "1301121017797062656"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2971608449"}, "tweet_id": "1301121244667039746"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "37877332"}, "tweet_id": "1301122713113821184"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1265211138494681089"}, "tweet_id": "1301123282985459713"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "188901992"}, "tweet_id": "1301124666950647819"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2542805927"}, "tweet_id": "1301125466540191745"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1253798525885915136"}, "tweet_id": "1301125954719363073"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "450433618"}, "tweet_id": "1301126686470217736"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "312183806"}, "tweet_id": "1301126909040959488"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "240796295"}, "tweet_id": "1301126916343242752"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1193283416365682688"}, "tweet_id": "1301127593773731851"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1375605480"}, "tweet_id": "1301128866493353987"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "450433618"}, "tweet_id": "1301128888844718083"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "312183806"}, "tweet_id": "1301128904539869186"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1193283416365682688"}, "tweet_id": "1301128987222200322"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "319669492"}, "tweet_id": "1301129006620831745"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1275159886263980032"}, "tweet_id": "1301130113317298177"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2542805927"}, "tweet_id": "1301131296312356865"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1703414018"}, "tweet_id": "1301131317418098693"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1070200929239080961"}, "tweet_id": "1301131495537549313"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1196576493478039553"}, "tweet_id": "1301132389599641600"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1251933456826863623"}, "tweet_id": "1301132644495822848"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2382138736"}, "tweet_id": "1301133867554922497"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2490483709"}, "tweet_id": "1301134401137508353"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4733206037"}, "tweet_id": "1301136759313625090"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "526014495"}, "tweet_id": "1301144738775658496"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "470150523"}, "tweet_id": "1301146364915658752"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1251933456826863623"}, "tweet_id": "1301148377527259136"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1019628154514702336"}, "tweet_id": "1301150491380940807"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4441136181"}, "tweet_id": "1301151646165143553"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "97037997"}, "tweet_id": "1301154542906675201"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2342778935"}, "tweet_id": "1301155118302232578"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1301157537631346690"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1222896293556523008"}, "tweet_id": "1301165526186631173"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1057972027917766656"}, "tweet_id": "1301168512807964672"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1251933456826863623"}, "tweet_id": "1301174921435979777"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3378458187"}, "tweet_id": "1301175402149355521"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "287858848"}, "tweet_id": "1301181496364019712"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "287858848"}, "tweet_id": "1301182350118842369"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2447285247"}, "tweet_id": "1301183462859300869"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1223307253236817922"}, "tweet_id": "1301191418715811842"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4229010568"}, "tweet_id": "1301193350935203844"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "114642048"}, "tweet_id": "1301194235576713217"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "223529798"}, "tweet_id": "1301200351459266565"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "42680434"}, "tweet_id": "1301204217315635202"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1053216952540323840"}, "tweet_id": "1301231649292562432"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1163989477"}, "tweet_id": "1301250582766911488"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4623699507"}, "tweet_id": "1301527877935079425"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2191109263"}, "tweet_id": "1301528104444272641"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "3600789733"}, "tweet_id": "1301718726971138048"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1303809009334382592"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1047343678296150016"}, "tweet_id": "1304200083324403714"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1306219972146999296"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1306744341550059520"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2712930637"}, "tweet_id": "1306751899786506241"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1306754360916029440"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "24627188"}, "tweet_id": "1306758075689435142"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1323379315"}, "tweet_id": "1306760810866176000"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1103075749072957440"}, "tweet_id": "1306762382904111106"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "973364324424134661"}, "tweet_id": "1306762475996676098"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "988446788372848642"}, "tweet_id": "1306767594473521152"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "747809624800268288"}, "tweet_id": "1306776033560010757"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "25251860"}, "tweet_id": "1306788858567307264"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "223529798"}, "tweet_id": "1306968011543199745"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "223529798"}, "tweet_id": "1306968343459426304"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "882900997651222529"}, "tweet_id": "1306968358840143872"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4733206037"}, "tweet_id": "1307234037250035717"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "18012660"}, "tweet_id": "1307554105079009280"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1007293555"}, "tweet_id": "1307665738585567233"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "85040410"}, "tweet_id": "1311071468223172614"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2543322702"}, "tweet_id": "1311219828968095744"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "174124727"}, "tweet_id": "1317248524371701760"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "999100031239118853"}, "tweet_id": "1324749971548065792"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1103075749072957440"}, "tweet_id": "1335293070628282374"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "834406759"}, "tweet_id": "1336127274098298882"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4441136181"}, "tweet_id": "1341663321204928512"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1250890146091864066"}, "tweet_id": "1341667747193872385"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1142696981145509888"}, "tweet_id": "1341698980334477317"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1342146678208475137"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "506407977"}, "tweet_id": "1342148001331093507"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "973364324424134661"}, "tweet_id": "1342212471608770567"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1314829710052995072"}, "tweet_id": "1342396249425719296"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1137505399"}, "tweet_id": "1343354258305904641"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1249318808"}, "tweet_id": "1349854739408842756"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "234926250"}, "tweet_id": "1353309604856389632"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "728650092870291456"}, "tweet_id": "1353391783120658435"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "923345918207946753"}, "tweet_id": "1353391874258710528"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "461899874"}, "tweet_id": "1353440695583793153"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "25677515"}, "tweet_id": "1353875878539886598"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2375142072"}, "tweet_id": "1354156249655484416"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "30903741"}, "tweet_id": "1354185635817345025"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2375142072"}, "tweet_id": "1354796693104025601"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "180490075"}, "tweet_id": "1360497050329223171"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1361449022385446917"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1250890146091864066"}, "tweet_id": "1364935271423352839"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1351950522987786242"}, "tweet_id": "1364935463035895810"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2431736265"}, "tweet_id": "1364949340079464452"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2431736265"}, "tweet_id": "1364950194383691777"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "2431736265"}, "tweet_id": "1364950782009827330"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "180490075"}, "tweet_id": "1365001245325361153"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1250890146091864066"}, "tweet_id": "1365004356035215363"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1327712210257408001"}, "tweet_id": "1365010816102195208"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1351950522987786242"}, "tweet_id": "1365015662897352711"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1439297204"}, "tweet_id": "1365020938874609667"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "981118005978501120"}, "tweet_id": "1365050202076372994"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "454276934"}, "tweet_id": "1365057701823315968"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "4163830413"}, "tweet_id": "1376550118208458752"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1250890146091864066"}, "tweet_id": "1382396884778631176"}, {"license": "gnip", "citation_ids": [89296426], "author": {"tweeter_id": "1439297204"}, "tweet_id": "1382587427278225408"}], "news": [{"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984276843&p=1pl&v=1&x=mv2WHwtTifW5xe2nmVSrBQ", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T00:00:00+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984330162&p=1pl&v=1&x=pwPIs1K_32VEvRhTKOwELw", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:28:02+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "AB Science : De nouvelles recherches ind\u00e9pendantes r\u00e9v\u00e8lent que le masitinib a une activit\u00e9 anti-virale in-vitro directe contre le virus SARS-CoV-2 et repr\u00e9sente un m\u00e9dicament candidat prometteur dans le traitement du COVID-19", "url": "http://ct.moreover.com/?a=42984284375&p=1pl&v=1&x=Ni537qfjLPBlwG1fukrStw", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:00+00:00", "summary": "Paris, 2 septembre 2020, 20h15 De nouvelles recherches ind\u00e9pendantes r\u00e9v\u00e8lent que le masitinib a une activit\u00e9 anti-virale in-vitro directe contre le virus SARS-CoV-2 et repr\u00e9sente un m\u00e9dicament candidat prometteur dans le traitement du COVID-19 AB\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984310726&p=1pl&v=1&x=txk7_XuAaXl-ycM97-R6aw", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:29+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984316463&p=1pl&v=1&x=i7V8tRI9ppU2wpY6J5PYgg", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:29+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984320144&p=1pl&v=1&x=eNH4xYv1Yf8UsZ7EosvZyQ", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:34:34+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984366732&p=1pl&v=1&x=DIP7Wdmu-hl7Z1Dvah-zNg", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:38:18+00:00", "summary": "** ** Paris, 02 September 2020, 8.15pm *New independent research reveals that masitinib **has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19* *AB Science SA* (NYSE Euronext \u2026", "author": {"name": "One News Page", "url": "http://www.onenewspage.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/709/normal/Screen_Shot_2017-07-31_at_14.28.13.png?1501507722"}}, {"title": "AB Science: New Independent Research Reveals That Masitinib Has Direct Anti-viral Activity Against The SARS-CoV-2 Virus In Vitro And Is A Promising Candidate For Treating COVID-19", "url": "http://ct.moreover.com/?a=42984375267&p=1pl&v=1&x=WivvQLhCbGWkZVkOL1_D5g", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:29+00:00", "summary": "pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB)...", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984386918&p=1pl&v=1&x=0jChmtwkf2ExuECuyC6jbA", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:38:18+00:00", "summary": "** ** Paris, 02 September 2020, 8.15pm *New independent research reveals that masitinib **has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19* *AB Science SA* (NYSE Euronext \u2026", "author": {"name": "One News Page", "url": "http://www.onenewspage.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/709/normal/Screen_Shot_2017-07-31_at_14.28.13.png?1501507722"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984437942&p=1pl&v=1&x=ISsKMSqV2kBxoT_13WaR4w", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:56:46+00:00", "summary": "\u00c2 Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 \u2026", "author": {"name": "Biz Wire Express", "url": "http://www.bizwireexpress.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/795/normal/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42984602639&p=1pl&v=1&x=fri6cor5lD_OgCAAHPvxEQ", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T19:26:24+00:00", "summary": "This research has shown for the first time that masitinib exerts a direct anti-viral effect on the SARS-CoV-2 virus, under in vitro conditions.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "https://www.trialsitenews.com/ab-science-new-independent-research-reveals-that-masitinib-has-direct-anti-viral-activity-against-the-sars-cov-2-virus-in-vitro-and-is-a-promising-candidate-for-treating-covid-19/", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:00+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext \u2013 FR0010557264 \u2013 AB\u2026", "author": {"name": "TrialSite News", "url": "https://www.trialsitenews.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/110/normal/Screenshot_2019-07-12_at_12.25.34.png?1562930787"}}, {"title": "Existing drug masitinib identified as potential inhibitor of SARS-CoV-2", "url": "http://ct.moreover.com/?a=42986174099&p=1pl&v=1&x=e6D2EWfJWrEONjhsh1MCaw", "license": "public", "citation_ids": [89296426], "posted_on": "2020-09-02T23:52:07+00:00", "summary": "Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease\u2026", "author": {"name": "The Medical News", "url": "http://www.news-medical.net/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/146/normal/image.png?1369927508"}}, {"title": "AB Science: New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19", "url": "http://ct.moreover.com/?a=42986225589&p=1pl&v=1&x=Fg92662QUXOiKHktIl9wYg", "license": "public", "citation_ids": [89296426, 89296426, 89296426], "posted_on": "2020-09-02T18:27:00+00:00", "summary": "Paris, 02 September 2020, 8.15pm New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating COVID-19 AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "AB Science's Mastinib Plus Gemcitabine Improves Survival, Descreases Pain, in Early Pancreatic Cancer", "url": "http://ct.moreover.com/?a=43714042701&p=1pl&v=1&x=RWQ38yodCExiCEz-x2iV_g", "license": "public", "citation_ids": [10902367, 52273061, 89296426], "posted_on": "2020-12-04T15:40:12+00:00", "summary": "A dual treatment approach consisting of gemcitabine combined with AB Science \u2019s masitinib, a highly selective tyrosine kinase inhibitor, was associated with significant increases in survival among patients with pancreatic cancer and pain, according\u2026", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "AB Science\u2019s Mastinib Plus Gemcitabine Improves Survival in Early Pancreatic Cancer", "url": "http://ct.moreover.com/?a=43715046831&p=1pl&v=1&x=j20jNOdTkJfIzATJUp006Q", "license": "public", "citation_ids": [10902367, 89296426, 52273061], "posted_on": "2020-12-04T17:15:51+00:00", "summary": "AB Science\u2019s Mastinib Plus Gemcitabine Improves Survival, Decreases Pain, in Early Pancreatic Cancer Published: Dec.", "author": {"name": "PharmaLive", "url": "https://www.pharmalive.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/705/normal/Capture3.PNG?1603951657"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086409377&p=1pl&v=1&x=He7tWK1Zhz2zeMn3lWCKRw", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:27:00+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086413652&p=1pl&v=1&x=DwO0KhOY-In5sHWnNmzi4A", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:26:49+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086413655&p=1pl&v=1&x=R4gaH0Fmr8zz3WAQGs7Rlg", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:32:36+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "AB Science Announces That A New Independent Publication Confirms That Masitinib Has Anti-vital Activity Against The SARS-CoV-2 Virus In Vitro And Is A Promising Candidate For Treating Covid-19", "url": "http://ct.moreover.com/?a=44086446796&p=1pl&v=1&x=t14VJGhSwQpVDWqwDNwGXA", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:26:49+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital ...", "url": "http://ct.moreover.com/?a=44086449960&p=1pl&v=1&x=m63iPeUoN92ZzhXm9pCUaw", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T02:26:00+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "BioMed Reports", "url": "http://www.biomedreports.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/913/normal/Screen_Shot_2016-02-02_at_15.18.15.png?1454426307"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086450675&p=1pl&v=1&x=0P6JDS34x3qWnXLmtXA-lg", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:26:49+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 ...", "url": "http://ct.moreover.com/?a=44086474972&p=1pl&v=1&x=2YvWRXHGOtCmU2eP9WQmNA", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:26:49+00:00", "summary": "/ EIN News / -- NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext \u2026", "author": {"name": "EINPresswire", "url": "https://www.einpresswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/542/normal/Capture12.PNG?1575872056"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086496859&p=1pl&v=1&x=xuABtykmEnn9Vqe6d-H_hA", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:51:15+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET AB Science SA (NYSE Euronext - FR0010557264 - AB\u2026", "author": {"name": "Biz Wire Express", "url": "http://www.bizwireexpress.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/795/normal/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086806869&p=1pl&v=1&x=S0B968RazNCBoDBC15mceQ", "license": "public", "citation_ids": [98605044, 89296426, 98605044, 89296426, 98605044], "posted_on": "2021-01-25T08:57:30+00:00", "summary": "AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44087203694&p=1pl&v=1&x=p0JxGZw8ZrUGzM_UT5QIjA", "license": "public", "citation_ids": [98605044, 89296426, 89296426, 98605044, 98605044], "posted_on": "2021-01-25T07:27:00+00:00", "summary": "am CET (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19.", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "AB Science announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44088897050&p=1pl&v=1&x=busL_yKImPOR4KOPe4dfHg", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T14:36:24+00:00", "summary": "AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced the publication of preclinical study results with masitinib in COVID-19.", "author": {"name": "FirstWord Pharma", "url": "https://www.firstwordpharma.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/684/normal/5.PNG?1603460857"}}, {"title": "AB SCIENCE : announces that a new independent publication confirms that masitinib has anti-vital activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19", "url": "http://ct.moreover.com/?a=44086398495&p=1pl&v=1&x=uYbrHWWz5M4B__EJ-4WPdQ", "license": "public", "citation_ids": [98605044, 98605044, 89296426, 89296426, 98605044], "posted_on": "2021-01-25T07:27:03+00:00", "summary": "NEW INDEPENDENT PUBLICATION CONFIRMS THAT MASITINIB HAS ANTI-VIRAL ACTIVITY AGAINST THE SARS-COV-2 VIRUS IN VITRO AND IS A PROMISING CANDIDATE FOR TREATING COVID-19 Paris, 25 January 2021, 8.30am CET (NYSE Euronext - FR0010557264 - AB) today\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44625976874&p=1pl&v=1&x=AWPXS7PLMFdJ7wJOoTGcJw", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:00+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronex\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "AB Science annonce aujourd\u2019hui la signature d'un accord de licence exclusif avec l'Universit\u00e9 de Chicago sur la pr\u00e9vention et le traitement de la Covid-19", "url": "http://ct.moreover.com/?a=44625977347&p=1pl&v=1&x=8XvkCyp12d9ITQBDz_LDvA", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:00+00:00", "summary": "COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA SIGNATURE D\u2019UNE COLLABORATION DE RECHERCHE AVEC L\u2019UNIVERSITE DE CHICAGO SUR LA PREVENTION ET LE TRAITEMENT DE LA COVID-19 AVEC LE MASITINIB ET D\u2019AUTRES MEDICAMENTS BREVETES PAR AB SCIENCE Paris, 6 avril\u2026", "author": {"name": "GlobeNewswire", "url": "https://www.globenewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/389/normal/B.PNG?1575002884"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44625985292&p=1pl&v=1&x=ROUWtfVHx8dqxKbAGtXMBw", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:05+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronex\u2026", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "AB SCIENCE : announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44625993416&p=1pl&v=1&x=_16104QMsi42DOZ_xv1xTQ", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:50:04+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET (Euronext \u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44626014959&p=1pl&v=1&x=Eh6_2RNANKwQQCVZJkOKqA", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:58:17+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronex\u2026", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "AB Science Announces The Signing Of An Exclusive Licensing Agreement With The University Of Chicago To Conduct Research For The Prevention And Treatment Of Covid-19", "url": "http://ct.moreover.com/?a=44626021646&p=1pl&v=1&x=t8neiVgWim8hFl0z-WYmcA", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:05+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronex\u2026", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "AB Science annonce aujourd\u2019hui la signature d'un accord de licence exclusif avec l'Universit\u00e9 de Chicago sur la pr\u00e9vention et le traitement de la Covid-19", "url": "http://ct.moreover.com/?a=44626022310&p=1pl&v=1&x=h0fUSes9GK68dNNKIr_npw", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T06:00:37+00:00", "summary": "COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA SIGNATURE D\u2019UNE COLLABORATION DE RECHERCHE AVEC L\u2019UNIVERSITE DE CHICAGO SUR LA PREVENTION ET LE TRAITEMENT DE LA COVID-19 AVEC LE MASITINIB ET D\u2019AUTRES MEDICAMENTS BREVETES PAR AB SCIENCE Paris, 6 avril\u2026", "author": {"name": "L'essentiel", "url": "http://www.lessentiel.lu/de/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/510/normal/Capture_essen.PNG?1569576406"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44626028817&p=1pl&v=1&x=bcmfTH4taGoy5TGvtxRgsg", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:05+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronex\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "AB Science annonce aujourd\u2019hui la signature d'un accord de licence exclusif avec l'Universit\u00e9 de Chicago sur la pr\u00e9vention et le traitement de la Covid-19", "url": "http://ct.moreover.com/?a=44626059615&p=1pl&v=1&x=ikvcONM57qNSiwAY-jEiqQ", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:00+00:00", "summary": "COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA SIGNATURE D\u2019UNE COLLABORATION DE RECHERCHE AVEC L\u2019UNIVERSITE DE CHICAGO SUR LA PREVENTION ET LE TRAITEMENT DE LA COVID-19 AVEC LE MASITINIB ET D\u2019AUTRES MEDICAMENTS BREVETES PAR AB SCIENCE Paris, 6 avril 2021\u2026", "author": {"name": "Yahoo! News", "url": "http://news.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/032/normal/yahoo_news.png?1369846922"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44626143296&p=1pl&v=1&x=-EB5tn2leHCwMqlq-f_f9g", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T06:26:14+00:00", "summary": "\u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2 \u00c2\u2026", "author": {"name": "Biz Wire Express", "url": "http://www.bizwireexpress.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/795/normal/Screen_Shot_2016-01-27_at_09.34.21.png?1453887297"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44626432593&p=1pl&v=1&x=GCXG2AiIUXytuCqTAnxJZg", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T07:22:53+00:00", "summary": "AB Science SA (Euronext - FR0010557264 - AB), together with the University of Chicago, today announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans infected with nidoviruses\u2026", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44628608114&p=1pl&v=1&x=K_en8_qlLGB5z7Zj4eekTw", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T05:49:00+00:00", "summary": "PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronext\u2026", "author": {"name": "Yahoo! Finance USA", "url": "http://finance.yahoo.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/620/normal/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}, {"title": "AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19", "url": "http://ct.moreover.com/?a=44629400272&p=1pl&v=1&x=CKnAghHcW2tiZnFQ6zTX5A", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T14:59:08+00:00", "summary": "Paris, April 6 2021, 8am CET AB Science SA (Euronext - FR0010557264 - AB), together with the University of Chicago, today announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans\u2026", "author": {"name": "FirstWord Pharma", "url": "https://www.firstwordpharma.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/005/684/normal/5.PNG?1603460857"}}, {"title": "AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS", "url": "https://trialsitenews.com/ab-science-announces-collaboration-with-the-university-of-chicago-to-conduct-research-for-the-prevention-and-treatment-of-covid-19-with-masitinib-and-other-ab-science-proprietary-drugs/", "license": "public", "citation_ids": [89296426, 89296426], "posted_on": "2021-04-06T22:30:00+00:00", "summary": "AB Science SA (Euronext \u2013 FR0010557264 \u2013 AB), together with the University of Chicago, today announce the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans infected with nidoviruses\u2026", "author": {"name": "TrialSite News", "url": "https://www.trialsitenews.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/110/normal/Screenshot_2019-07-12_at_12.25.34.png?1562930787"}}], "blogs": [{"title": "Mastinib, Sclerosis and COVID-19", "url": "https://multiple-sclerosis-research.org/2020/09/mastinib-sclerosis-and-covid-19/?utm_source=rss&utm_medium=rss&utm_campaign=mastinib-sclerosis-and-covid-19", "license": "public", "citation_ids": [788773, 63265788, 89296426, 3307926, 788773], "posted_on": "2020-09-14T07:00:00+00:00", "summary": "Later NDG will report the results of the Mastinib trial in Progressive MS reported at ACTRIS/ECTRIMS 2020. Mastinib is a tyrosine kinase inhibitior, which is distinct from a Brutons Tyrosine Kinase Inhibitor that inhibits B cells. Mastinib inhibits a numbe", "author": {"name": "Multiple Sclerosis Research", "url": "http://multiple-sclerosis-research.blogspot.com/", "description": "A blog for people with MS and their families, by Barts and The London School of Medicine and Dentistry."}}]}, "score": 219.604, "images": {"small": "https://badges.altmetric.com/?size=64&score=220&types=mbtttttt", "medium": "https://badges.altmetric.com/?size=100&score=220&types=mbtttttt", "large": "https://badges.altmetric.com/?size=180&score=220&types=mbtttttt"}}